diabetestalk.net

Metformin Hydrochloride Sustained Release Tablets Formulation

Study On Sustained-release Metformin Hydrochloride From Matrix Tablet: Influence Of Hydrophilic Polymers And In Vitro Evaluation Wadher Kj, Kakde Rb, Umekar Mj - Int J Pharma Investig

Study On Sustained-release Metformin Hydrochloride From Matrix Tablet: Influence Of Hydrophilic Polymers And In Vitro Evaluation Wadher Kj, Kakde Rb, Umekar Mj - Int J Pharma Investig

The overall objective of the present work was to develop an oral sustained-release (SR) metformin tablet prepared by the direct compression method, using hydrophilic hydroxylpropylmethylcellulose (HPMC) and Guar gum polymer alone and in combination at different concentrations. Metformin hydrochloride (HCl), a biguanide, has a relatively short plasma half-life and low absolute bioavailability. All the batches were evaluated for thickness, weight variation, hardness and drug content uniformity and in vitro drug release. Mean dissolution time is used to characterize the drug release rate from a dosage form, and indicates the drug release-retarding efficiency of the polymer. The hydrophilic matrix of HPMC alone could not control the Metformin release effectively for 12 h whereas when combined with Guar gum, it could slow down the release of drug and, thus, can be successfully employed for formulating SR matrix tablets. Fitting the data to the Korsmeyer equation indicated that diffusion along with erosion could be the mechanism of drug release. Similarity factor 2 values suggest that the test and reference profiles are identical. Keywords:Guar gum, hydroxylpropylmethylcellulose K100M, matrix tablets, release kinetics, similarity factors Wadher KJ, Kakde RB, Umekar MJ. Study on sustained-release metformin hydrochloride from matrix tablet: Influence of hydrophilic polymers and in vitro evaluation. Int J Pharma Investig 2011;1:157-63 Wadher KJ, Kakde RB, Umekar MJ. Study on sustained-release metformin hydrochloride from matrix tablet: Influence of hydrophilic polymers and in vitro evaluation. Int J Pharma Investig [serial online] 2011 [cited2018 Apr 30];1:157-63. Available from: Sustained-release (SR) oral delivery systems are designed to achieve therapeutically effective conc Continue reading >>

Formulation And Evaluation Of Sitagliptin Phosphate And Metformin Hydrochloride Trilayered Tablets | Maringanti | International Journal Of Drug Delivery

Formulation And Evaluation Of Sitagliptin Phosphate And Metformin Hydrochloride Trilayered Tablets | Maringanti | International Journal Of Drug Delivery

Formulation and Evaluation of Sitagliptin Phosphate and Metformin Hydrochloride Trilayered tablets Prathima Srinivas Maringanti, Chaitanya Nalagonda Sitagliptin phosphate when used alone is an oral anti hyperglycemic drug of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It is available as tablets under trade name JANUVIA. Metformin hydrochloride is used alone in the form of biguanide anti hyperglycemic agent for treating non-insulin-dependent diabetes mellitus (NIDDM) and is available as both conventional and sustained release tablets. The objective of the present study was to develop a trilayered tablet of immediate release Sitagliptin phosphate layer and sustained release Metformin Hydrochloride layer. Apart from the aesthetic appeal this trilayered tablet is expected to improve glucose tolerance in patients with the type 2 diabetes by lowering both basal and postprandial plasma glucose, reducing the dose, reducing frequency of administration and dose related gastrointestinal side effects of metformin and improve its bioavailability thus improving the patient compliance. Metformin Hydrochloride has biological half-life of nearly 6 hours. An attempt was made to sustain its release by using two different polymers in two layers. Preformulation studies including drug excipient compatibility studies were conducted for both drugs. Different formulations of sustained release Metformin HCl tablets were prepared by using a combination of hydrophilic polymers like HPMC K100, HPMC K4M, HPMC K15 M, pH sensitive polymer Carbopol 971P, retarding polymer Ethyl cellulose and Low substituted hydroxy propyl cellulose. Sitagliptin immediate release formulations were prepared using cross povidone, croscarmellose sodium and sodium starch glycolate as super disintegrants. The tablet Continue reading >>

Us7214387b2 - Sustained Release Formulations Of Metformin - Google Patents

Us7214387b2 - Sustained Release Formulations Of Metformin - Google Patents

US7214387B2 - Sustained release formulations of metformin - Google Patents Sustained release formulations of metformin US7214387B2 US10630239 US63023903A US7214387B2 US 7214387 B2 US7214387 B2 US 7214387B2 US 10630239 US10630239 US 10630239 US 63023903 A US63023903 A US 63023903A US 7214387 B2 US7214387 B2 US 7214387B2 Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.) Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.) A61MEDICAL OR VETERINARY SCIENCE; HYGIENE A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient A61MEDICAL OR VETERINARY SCIENCE; HYGIENE A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES A61K31/00Medicinal preparations containing organic active ingredients A61K31/155Amidines (), e.g. guanidine (H2NC(=NH)NH2), isourea (N=C(OH)NH2), isothiourea (N=C(SH)NH2) A61MEDICAL OR VETERINARY SCIENCE; HYGIENE A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins

Comparison Of Conventional And Sustained-release Formulation Of Metformin In Type 2 Diabetics

Comparison Of Conventional And Sustained-release Formulation Of Metformin In Type 2 Diabetics

DOI: Abstract Background: To investigate the effects of metformin sustained-release (MSR) compared with metformin immediate-release (MIR) on glycaemic control, blood pressure, lipid profile and metabolic parameters like weight, waist circumference in type 2 diabetes. Methods: A prospective, randomized, double blind study was conducted at tertiary healthcare and teaching hospital at Pune, Maharashtra. After obtaining institutional ethical committee approval and written informed consent, 40 newly diagnosed type 2 diabetic patient were randomly assigned to receive metformin immediate release formulation (MIR) 500 mg once 1 week and then twice daily and metformin sustained release formulation (MSR) 500 mg once 1 week and then 1000mg once daily for 18 weeks. Fasting and post prandial blood glucose level (BGL), HbA1c, blood pressure, lipid profile, weight and waist circumference, were recorded at the start and end of study. Results: Both MIR and MSR significantly decreased fasting; post prandial BGL and HbA1c at 18 weeks. But no significant difference was seen between two groups. Study did not show any effect on blood pressure and on lipid profile. Both formulations decreased obesity as evident by significant reduction in weight and waist circumference. All patients tolerated both formulations of metformin. Though overall incidences of adverse effects are less with sustained release formulation, difference was not significant between two groups. Conclusions: To conclude, both metformin immediate release and sustained release formulations achieved comparable glycaemic control and sustained release formulation would be as effective as immediate release formulation with advantage of being reduce daily intake of tablets. References Powers AC. Diabetes mellitus. In D.L. Kasper, E. Continue reading >>

Formulation And Evaluation Of Multilayered Tablets Of Pioglitazone Hydrochloride And Metformin Hydrochloride

Formulation And Evaluation Of Multilayered Tablets Of Pioglitazone Hydrochloride And Metformin Hydrochloride

Formulation and Evaluation of Multilayered Tablets of Pioglitazone Hydrochloride and Metformin Hydrochloride Y. Ankamma Chowdary ,1 Ramakrishna Raparla ,2and Muramshetty Madhuri 2 1Department of Pharmaceutics, NRI College of Pharmacy, Pothavarappadu Village, Krishna District, Andhra Pradesh 521 212, India 2Department of Pharmaceutics, Vaageswari Institute of Pharmaceutical Sciences, Beside LMD Police Station, Karimnagar, Andhra Pradesh 505 481, India Received 28 November 2013; Revised 15 February 2014; Accepted 2 March 2014; Published 12 May 2014 Copyright 2014 Y. Ankamma Chowdary et al. This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In the treatment of type 2 diabetes mellitus a continuous therapy is required which is a more complex one. As in these patients there may be a defect in both insulin secretion and insulin action exists. Hence, the treatment depends on the pathophysiology and the disease state. In the present study, multilayered tablets of pioglitazone hydrochloride 15 mg and metformin hydrochloride 500 mg were prepared in an attempt for combination therapy for the treatment of type 2 diabetes mellitus. Pioglitazone HCl was formulated as immediate release layer to show immediate action by direct compression method using combination of superdisintegrants, namely, crospovidone and avicel PH 102. Crospovidone at 20% concentration showed good drug release profile at 2 hrs. Metformin HCl was formulated as controlled release layer to prolong the drug action by incorporating hydrophilic polymers such as HPMC K4M by direct compression method and guar gum by wet granulation method in order to sustain Continue reading >>

Preparation Of Metformin Hydrochlorideextended Release Matrix Tablets By Directcompression Method And Its In Vitro Evaluation

Preparation Of Metformin Hydrochlorideextended Release Matrix Tablets By Directcompression Method And Its In Vitro Evaluation

British Journal of Pharmaceutical Research British Journal of Pharmaceutical Research, ISSN: 2231-2919,Vol.: 4, Issue.: 24 (16-31 December) Preparation of Metformin Hydrochloride Extended Release Matrix Tablets by Direct Compression Method and Its In vitro Evaluation Mohammad Raquibul Hasan1*, Md. Abul Hossen2, Aumit Roy1, Tufikul Islam1 and Md. Saiful Islam Pathan2 1Department of Pharmacy, Jahangirnagar University, Savar, Dhaka 1342, Bangladesh. 2Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh. Aims: Metformin Hydrochloride, a biguanide, is an orally active antihyperglycemic agent, used in the treatment of non-insulin dependent diabetes mellitus (NIDDM). It has relatively short plasma half life, low absolute bioavailability. Extended release formulation of Metformin Hydrochloride by direct compression method has significant challenges due to its poor inherent compressibility and high dose. The aim of this study was to develop extended release tablets of Metformin Hydrochloride by direct compression method and In vitro evaluation. Study Design: Nine different formulations were made by varying drug-polymer ratio and were subjected to different physical property tests of the powder blend as well as prepared tablets, followed by dissolution test. Place and Duration of Study: Department of Pharmacy, State University of Bangladesh, Dhaka, Bangladesh, between January 2013 and July 2013. Methodology: Nine formulations of Metformin Hydrochloride matrix tablets - F-1, F-2, F-3, F-4, F-5, F-6, F-7, F-8 and F-9 - were prepared by direct compression method using release retarding materials, Methocel K100 MCR Premium (derivative of hydroxypropyl methylcellulose - HPMC) and Xanthan gum. The drug and polymer ratio were 1:0.41, 1:0.45, 1:0.49, 1:0.59, 1:0.63, Continue reading >>

Formulation And Evaluation Of Metformin Hydrochloride Sustained-release Oral Matrix Tablets | Bookya | Asian Journal Of Pharmaceutical And Clinical Research

Formulation And Evaluation Of Metformin Hydrochloride Sustained-release Oral Matrix Tablets | Bookya | Asian Journal Of Pharmaceutical And Clinical Research

FORMULATION AND EVALUATION OF METFORMIN HYDROCHLORIDE SUSTAINED-RELEASE ORAL MATRIX TABLETS Padmaja Bookya, Ramakrishna Raparla, Ramakrishna Raparla, Harikishan Prasad Sriramula, Ramakrishna Raparla, Sunitha Tarrigopula, Harikishan Prasad Sriramula, Sridhar Vanga, Ramakrishna Raparla, Harikishan Prasad Sriramula, Sunitha Tarrigopula, Harikishan Prasad Sriramula, Sridhar Vanga, Sunitha Tarrigopula, Sunitha Tarrigopula, Sridhar Vanga, Sridhar Vanga Objective: The aim of this investigation was to develop and optimize metformin hydrochloride matrix tablets for sustained release application. The sustained release matrix tablet of metformin hydrochloride was prepared by wet granulation technique using chitosan, xanthan gum, and hydroxypropyl methylcellulose at varying concentrations. Material and Methods: Extended release of metformin hydrochloride matrix tablets was prepared by wet granulation method. The influence of varying the polymer ratios was evaluated. The excipients used in this study did not alter physicochemical properties of the drug. Results: All the batches were evaluated for thickness, weight variation, hardness, and drug content uniformity. The in vitro drug dissolution study was carried out using USP apparatus Type II, paddle method, and the release mechanisms were explored. Mean dissolution time is used to characterize drug release rate from a dosage form and indicates the drug release is retarding efficiency of the polymer. This study revealed that as the concentration of matrix material increased, drug release from matrices decreased. This may be due to slower penetration of the dissolution medium into the matrices. Conclusion: Formulation with chitosan MS1 drug release was 86%, xanthan gum MS489%, and finally MS7 with hydroxypropyl methyl cellulose which Continue reading >>

Formulation And Design Of Sustained Release Matrix Tablets Of Metformin Hydrochloride: Influence Of Hypromellose And Polyacrylate Polymers Roy H, Brahma Ck, Nandi S, Parida Kr - Int J App Basic Med Res

Formulation And Design Of Sustained Release Matrix Tablets Of Metformin Hydrochloride: Influence Of Hypromellose And Polyacrylate Polymers Roy H, Brahma Ck, Nandi S, Parida Kr - Int J App Basic Med Res

Oral drug delivery is the most widely utilized routes for administration of drugs, which has been explored for systemic delivery via various pharmaceutical products as different dosage form. [1] In long-term therapy for the treatment of chronic disorders, conventional formulations are required to be administered frequently in multiple dosage regimens, and therefore have several undesirable effects. Hence, in order to reduce the drawback associated with multiple dosing, controlled or sustained release solid unit dosage forms as tablets were developed. [2] They often produce better patient compliance, maintain uniform drug therapeutic level, are cost-effective, have broad regulatory acceptance, reduce dose as well as side-effects, and increase the safety margin for high-potency therapeutic agents. [3] Diabetes mellitus, simply referred to as diabetes, is a group of metabolic diseases in which a person has high level of blood sugar. The possible causative reason maybe that the body does not produce enough insulin, or cells do not respond to the insulin that is produced by the pancreatic cells. [4] In developing countries, the majority of people suffering from diabetes are in the 45-64 year age range. [5] As per the World Health Organisation (WHO) report, the total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030. [6] , [7] Metformin hydrochloride is the first-line drug of choice for the treatment of type II diabetes, especially, in overweight and obese people and those having normal kidney function. [8] Metformin helps to improve hyperglycemia primarily by suppressing glucose production by the liver (hepatic gluconeogenesis). It does activate adenosine monophosphate-activated protein kinase, an enzyme that plays an import Continue reading >>

Prime Pubmed | Formulation And Evaluation Of A Sustained-release Tablets Of Metformin Hydrochloride Using Hydrophilic Synthetic And Hydrophobic Natural Polymer

Prime Pubmed | Formulation And Evaluation Of A Sustained-release Tablets Of Metformin Hydrochloride Using Hydrophilic Synthetic And Hydrophobic Natural Polymer

Type your tag names separated by a space and hit enter Formulation and evaluation of a sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers. Metformin hydrochloride has relatively short plasma half-life, low absolute bioavailability. The need for the administration two to three times a day when larger doses are required can decrease patient compliance. Sustained release formulation that would maintain plasma level for 8-12 h might be sufficient for daily dosing of metformin. Sustained release products are needed for metformin to prolong its duration of action and to improve patient compliances. The overall objective of this study was to develop an oral sustained release metformin hydrochloride tablet by using hydrophilic Eudragit RSPO alone or its combination with hydrophobic natural polymers Gum copal and gum damar as rate controlling factor. The tablets were prepared by wet granulation method. The in vitro dissolution study was carried out using USP 22 apparatus I, paddle method and the data was analysed using zero order, first order, Higuchi, Korsmeyer and Hixson-Crowell equations. The drug release study revealed that Eudragit RSPO alone was unable to sustain the drug release. Combining Eudragit with gum Copal and gum Damar sustained the drug release for more than 12 h. Kinetic modeling of in vitro dissolution profiles revealed the drug release mechanism ranges from diffusion controlled or Fickian transport to anomalous type or non-Fickian transport. Fitting the in vitro drug release data to Korsmeyer equation indicated that diffusion along with erosion could be the mechanism of drug release. Wadher KJ, Kakde RB, Umekar MJ: "Formulation and evaluation of a sustained-release tablets of metformin hydrochlori Continue reading >>

Formulation Of Extended-release Metformin Hydrochloride Matrix Tablets | Nanjwade | Tropical Journal Of Pharmaceutical Research

Formulation Of Extended-release Metformin Hydrochloride Matrix Tablets | Nanjwade | Tropical Journal Of Pharmaceutical Research

Tropical Journal of Pharmaceutical Research Log in or Register to get access to full text downloads. Formulation of Extended-Release Metformin Hydrochloride Matrix Tablets Purpose: To develop and characterize an oral extended-release matrix tablet of metformin hydrochloride using a combination of a hydrophobic carrier and a hydrophilic polymer, and two types of formulation techniques. Methods: Various metformin hydrochloride formulations containing a hydrophobic carrier (stearic acid) and a hydrophilic polymer (polyethylene oxide) were prepared using a 32 factorial design. Two types of formulation techniques melt granulation and direct compression were evaluated. The influence of the carrier, polymer and preparation method on metformin release from the formulations in vitro as well as other physicochemical properties were studied. The release data were subjected to various release kinetic models and also compared with those of a commercial brand. Results: The physicochemical characteristics of all the granules and tablets were generally satisfactory. Optimization results indicate that the release rate of metformin HCl was directly proportional to the levels of stearic acid (SA) and polyethylene oxide (PEO) in the tablet formulations. Release rate was also dependent on the method of granulation used. Kinetic analysis showed that the formulation containing 30 %w/w of polymer exhibited release similar to that of the commercial brand with a similarity factor (f2) of 81.1. Melt granulation was more effective in extending drug release than direct compression. Release mechanism followed most closely the Korsemeyer-Peppas model with a correlation coefficient (r2) and 0.991. Conclusion: The use of a hydrophobic carrier along with a hydrophilic polymer effectively controls the i Continue reading >>

Formulation Evaluation Of Extended-release Solid Dispersion Of Metformin Hydrochloride - Sciencedirect

Formulation Evaluation Of Extended-release Solid Dispersion Of Metformin Hydrochloride - Sciencedirect

Formulation Evaluation of Extended-Release Solid Dispersion of Metformin Hydrochloride Author links open overlay panel S.A.Patil B.S.Kuchekar A.R.Chabukswar S.C.Jagdale Get rights and content The purpose of this research was to formulate and characterize solid dispersion (SD) of metformin hydrochloride using methocel K100M as the carrier by the solvent evaporation and cogrinding method. The influence of drug polymer ratio on drug release was studied by dissolution tests. Characterization was performed by fourier transform spectroscopy (FTIR), ultraviolet, differential scanning calorimetry and X-ray powder diffractometry. The optimized formulation was subjected to accelerated stability testing as per ICH guidelines. Release data were examined kinetically. SD with 1:4 and 1:5 ratio of drug to polymer obtained by solvent evaporation and cogrinding were selected as the best candidates suitable for prolonged-release oral dosage form of metformin. Continue reading >>

Mathematical Model-based Accelerated Development Of Extended-release Metformin Hydrochloride Tablet Formulation

Mathematical Model-based Accelerated Development Of Extended-release Metformin Hydrochloride Tablet Formulation

, Volume 17, Issue4 , pp 10071013 | Cite as Mathematical Model-Based Accelerated Development of Extended-release Metformin Hydrochloride Tablet Formulation Research Article Theme: Leveraging BCS Classification and in-silico Modeling for Product Development Theme: Leveraging BCS Classification and in-silico Modeling for Product Development A computational fluid dynamic (CFD) model was developed to predict metformin release from a hydroxypropylmethylcellulose (HPMC) matrix-based extended-release formulation that took into consideration the physical and chemical properties of the drug substance, composition, as well as size and shape of the tablet. New high dose strength (1000mg) tablet geometry was selected based on the surface area/volume (SA/V) approach advocated by Lapidus/Lordi/Reynold to obtain the desired equivalent metformin release kinetics. Maintaining a similar SA/V ratio across all extended-release metformin hydrochloride (Met XR) tablet strengths that had different geometries provided similar simulations of dissolution behavior. Experimental dissolution profiles of three lots of high-strength tablets agreed with the simulated release kinetics. Additionally, a pharmacokinetic absorption model was developed using GastroPlus software and known physicochemical, pharmacokinetic, and in vitro dissolution properties of metformin to predict the clinical exposure of the new high strength (1000mg) tablet prior to conducting a human clinical bioequivalence study. In vitro metformin release kinetics were utilized in the absorption model to predict exposures in humans for new 1000-mg Met XR tablets, and the absorption model correctly projected equivalent in vivo exposure across all dose strengths. A clinical bioequivalence study was pursued based on the combined modeling Continue reading >>

Formulation And Evaluation Of A Sustained-release Tablets Of Metformin Hydrochloride Using Hydrophilic Synthetic And Hydrophobic Natural Polymers.

Formulation And Evaluation Of A Sustained-release Tablets Of Metformin Hydrochloride Using Hydrophilic Synthetic And Hydrophobic Natural Polymers.

Metformin hydrochloride has relatively short plasma half-life, low absolute bioavailability. The need for the administration two to three times a day when larger doses are required can decrease patient compliance. Sustained release formulation that would maintain plasma level for 8-12 h might be sufficient for daily dosing of metformin. Sustained release products are needed for metformin to prolong its duration of action and to improve patient compliances. The overall objective of this study was to develop an oral sustained release metformin hydrochloride tablet by using hydrophilic Eudragit RSPO alone or its combination with hydrophobic natural polymers Gum copal and gum damar as rate controlling factor. The tablets were prepared by wet granulation method. The in vitro dissolution study was carried out using USP 22 apparatus I, paddle method and the data was analysed using zero order, first order, Higuchi, Korsmeyer and Hixson-Crowell equations. The drug release study revealed that Eudragit RSPO alone was unable to sustain the drug release. Combining Eudragit with gum Copal and gum Damar sustained the drug release for more than 12 h. Kinetic modeling of in vitro dissolution profiles revealed the drug release mechanism ranges from diffusion controlled or Fickian transport to anomalous type or non-Fickian transport. Fitting the in vitro drug release data to Korsmeyer equation indicated that diffusion along with erosion could be the mechanism of drug release. Continue reading >>

Formulation And Evaluation Of Sustained Release Metformin Hydrochloride Matrix Tablet Using Natural Polysaccharide

Formulation And Evaluation Of Sustained Release Metformin Hydrochloride Matrix Tablet Using Natural Polysaccharide

Formulation and Evaluation of Sustained Release Metformin Hydrochloride Matrix Tablet Using Natural Polysaccharide Dharmendra Solanki1*, Surendra kumar Jain2, Sujata Mahapatra3 1. Charak Institute of Pharmacy, Mandleshwar, M.P, India 2. Sagar Institute of Research and Technology, Bhopal, M.P, India 3. Khallikote College, Berhampur,Orissa, India. The aim of this investigation was to develop and optimize Metformin Hydrochloride matrix tablets for sustained release application. The sustained release matrix tablet of Metformin Hydrochloride was prepared by wet granulation technique using Tamarind pulp polysaccharide. The polysaccharides obtained after extracted from natural source and evaluated for their colour, viscosity and pH. The prepared tablet was evaluated for their hardness, friability, drug content, In vitro dissolution, swelling studies. In vitro drug release profiles of Metformin Hydrochloride Tablet using Tamarind pulp polysaccharide formulation release of drug from the Tablet exhibited a sustained & controlled pattern over an extended time period. .The tablet formulation TF-1 was found to release the drug of about 95% after 12 hrs, The tablet formulation TF-5 was found to release the drug of about 70% after 12 hrs, thus concluded to have sustained drug release for longer period of time in sustained and controlled pattern when compared to other tablet formulations. Using Higuchis Model and the Korsmeyer equation, the drug release mechanism from the sustained release tablets was found to be Anomalous (non-Fickian) diffusion. Compatibility study confirmed that interactions do not exist between the drug and polymer. Keywords: Metformin Hydrochloride, Tamarind pulp Polysaccharide, matrix tablet, Sustained Release. Swelling index. American Journal of PharmTech Resea Continue reading >>

Formulation And Evaluation Of A Sustained-release Tablets Of Metformin Hydrochloride Using Hydrophilic Synthetic And Hydrophobic Natural Polymers

Formulation And Evaluation Of A Sustained-release Tablets Of Metformin Hydrochloride Using Hydrophilic Synthetic And Hydrophobic Natural Polymers

Formulation and Evaluation of a Sustained-Release Tablets of Metformin Hydrochloride Using Hydrophilic Synthetic and Hydrophobic Natural Polymers Department of Pharmaceutical Technology, Smt. Kishoritai Bhoyar College of Pharmacy, Kamptee, Nagpur-441 002, India 1University Department of Pharmaceutical Sciences, R. T. M. Nagpur University Nagpur-440 010, India *Address for correspondence E-mail: [email protected] Received 2010 Sep 16; Revised 2011 Apr 27; Accepted 2011 Apr 29. Copyright : Indian Journal of Pharmaceutical Sciences This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC. Metformin hydrochloride has relatively short plasma half-life, low absolute bioavailability. The need for the administration two to three times a day when larger doses are required can decrease patient compliance. Sustained release formulation that would maintain plasma level for 8-12 h might be sufficient for daily dosing of metformin. Sustained release products are needed for metformin to prolong its duration of action and to improve patient compliances. The overall objective of this study was to develop an oral sustained release metformin hydrochloride tablet by using hydrophilic Eudragit RSPO alone or its combination with hydrophobic natural polymers Gum copal and gum damar as rate controlling factor. The tablets were prepared by wet granulation method. The in vitro dissolution study was carried out using USP 22 apparatus I, paddle method and the data was analysed using zero order, first order, Higuchi, Korsmeyer and Hixson-Cro Continue reading >>

More in diabetes